Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
Gynecologic Oncology|August 2, 2014
Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinomaNeil B Desai, Marisa A Kollmeier, Vicky Makker, et al.
Gynecologic Oncology|August 30, 2008
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcomaVicky Makker, Nadeem R Abu-Rustum, Kaled M Alektiar, et al.
American Journal of Ophthalmology Case Reports|July 18, 2022
Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibitionWilliam Foulsham, Benjeil Z Edghill, O D Julia Canestraro, et al.
Gynecologic Oncology|May 19, 2023
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendationsBobbie J Rimel, Erin K Crane, June Hou, et al.
Gynecologic Oncology|April 19, 2015
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NVicky Makker, Virginia L Filiaci, Lee-May Chen, et al.
Gynecologic Oncology|October 24, 2022
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancerMaria Rubinstein, Sherry Shen, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Real-world clinical outcomes of lenvatinib+pembrolizumab for the treatment of patients with non-microsatellite instability-high/mismatch repair proficient recurrent or advanced endometrial cancer following prior systemic therapy in the United StatesSiddhi Korgaonkar, Vimalanand S Prabhu, Rohan C Parikh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 31, 2016
An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial CarcinomaLusha W Liang, Alexendar R Perez, Nicholas A Cangemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid TumorsVicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
Gynecologic Oncology|November 21, 2008
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancerKaled M Alektiar, Vicky Makker, Nadeem R Abu-Rustum, et al.
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
Gynecologic Oncology|August 2, 2014
Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinomaNeil B Desai, Marisa A Kollmeier, Vicky Makker, et al.
Gynecologic Oncology|August 30, 2008
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcomaVicky Makker, Nadeem R Abu-Rustum, Kaled M Alektiar, et al.
American Journal of Ophthalmology Case Reports|July 18, 2022
Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibitionWilliam Foulsham, Benjeil Z Edghill, O D Julia Canestraro, et al.
Gynecologic Oncology|May 19, 2023
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendationsBobbie J Rimel, Erin K Crane, June Hou, et al.
Gynecologic Oncology|April 19, 2015
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NVicky Makker, Virginia L Filiaci, Lee-May Chen, et al.
Gynecologic Oncology|October 24, 2022
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancerMaria Rubinstein, Sherry Shen, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Real-world clinical outcomes of lenvatinib+pembrolizumab for the treatment of patients with non-microsatellite instability-high/mismatch repair proficient recurrent or advanced endometrial cancer following prior systemic therapy in the United StatesSiddhi Korgaonkar, Vimalanand S Prabhu, Rohan C Parikh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 31, 2016
An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial CarcinomaLusha W Liang, Alexendar R Perez, Nicholas A Cangemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid TumorsVicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
Gynecologic Oncology|November 21, 2008
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancerKaled M Alektiar, Vicky Makker, Nadeem R Abu-Rustum, et al.
Pageof 14